海尔生物突遭私募举牌！久实投资具有国资背景

Core Viewpoint - Haier Biomedical has been targeted for a stake acquisition by Jiushi Investment, reaching a 5% shareholding threshold, indicating confidence in the company's future development and potential for collaborative growth [1][4][2]. Group 1: Investment Details - Jiushi Investment's Jiushi Preferred No. 1 Fund acquired 15,897,900 shares of Haier Biomedical, representing 5% of the total share capital [4]. - The investment was made through secondary market transactions and was funded by Jiushi Investment's own capital [4]. - Jiushi Investment has no immediate plans to increase or decrease its stake in Haier Biomedical within the next 12 months [4]. Group 2: Company Background - Haier Biomedical is a subsidiary of Haier Group's health ecosystem brand, established in October 2005 and listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in October 2019 [7]. - The company has faced a continuous decline in stock price over the past four years, with significant drops of 29.83%, 35.46%, 12%, and 6.38% in the years 2022, 2023, 2024, and 2025 respectively [10]. Group 3: Financial Performance - In the first half of 2025, Haier Biomedical reported revenue of 1.196 billion yuan, a decrease of 2.27% year-on-year, and a net profit of 143 million yuan, down 39.09% year-on-year [8]. - The company attributes the profit decline to external factors, new capacity ramp-up, and strategic investments, but anticipates improvement as industry conditions recover [8]. - The overseas business showed strong growth, with revenue of 427 million yuan, a year-on-year increase of 30.17%, achieving the highest quarterly revenue and growth rate since 2023 in the second quarter [9].